Clear cell renal cell carcinoma (ccRCC) is the most common adult renal neoplasm and its incidence continues to increase. Collagen is the most abundant extracellular matrix protein in stroma, and contributes to the development and progression of ccRCC. We examined the human collagen type XXIII α1 chain (COL23A1) expression in ccRCC and the relationship between COL23A1 and patients' survival. We found COL23A1 mRNA was elevated in tumor compared with adjacent normal tissues, which was further validated by TCGA cohort. IHC results from 151 ccRCC cases suggested that high COL23A1 expression correlated with larger tumor size (P = 0.017) and advanced T stage (P = 0.011). The overall survival (OS) was shorter for ccRCC patients with high COL23A1 expression (P = 0.002). In multivariate analysis, high COL23A1 expression was an independent prognostic factor of OS (HR: 3.024, P = 0.017). Furthermore, COL23A1 knockdown repressed proliferation of ccRCC cell lines by blocking cell cycle progression. Cell adhesion and migration capacity was also downregulated by knockdown of COL23A1. Our data indicate that COL23A1 may be a novel prognostic indicator in ccRCC and might be a specific and accessible biomarker as well as a potential new target for clinical diagnosis of ccRCC.
Renal cell carcinoma (RCC) is the second leading cause of death among all types of urologic cancer and accounts for approximately 3% of all adult malignancies 1, 2 . The most common subtype of RCC is clear cell renal cell carcinoma (ccRCC), which accounts for 75-80% of all diagnosed cases 3 . ccRCC is characterized by extremely high rates of local invasion, malignancy, and mortality, and resistance to chemotherapy and radiotherapy 4 . Approximately 25-30% of ccRCC patients present with metastatic disease at the time of diagnosis 5 . Recent advancements in ccRCC treatment strategies, including targeted therapies, have been achieved great therapeutic improvements 6, 7 ; however, most treated patients eventually develop progressive disease due to acquired resistance 8, 9 , resulting in poor prognosis. Insight into the mechanisms of ccRCC pathogenesis and progression may contribute to the development of novel strategies for the treatment of ccRCC.
The extracellular matrix (ECM) is a highly organized structure with many physiological and pathological roles 10 . Modification of the ECM composition through a large array of molecules has been proven to be crucial for tumor initiation and progression 11 . Collagens are the major constituent of the tumor ECM component and play a crucial role in the development of tumors [12] [13] [14] . The human collagen type XXIII α1 chain (encoded by COL23A1) is a member of the transmembrane collagens, a subfamily of the nonfibrillar collagens 15 . The correlation between upregulation of collagen XXIII and tumor progression has been previously investigated in several types of cancer [15] [16] [17] [18] . Wozniak et al. also reported that COL23A1 was highly expressed in ccRCC 19 . However, no functional analysis was performed in ccRCC in the previous study. Therefore, the primary aim of this study was to investigate whether COL23A1 expression is correlated with clinicopathological features of ccRCC and patient survival. In addition, we sought to determine the function of COL23A1 in ccRCC using in vitro experiments.
Results

COL23A1 is strongly upregulated in ccRCC tissues.
To investigate the COL23A1 expression alterations in ccRCC, mRNA expression profiling was performed with 19 pairs of primary non-metastatic ccRCC tissue samples and adjacent normal tissues (ANTs). The tissue profiles demonstrated that COL23A1 mRNA expression was upregulated in primary non-metastatic ccRCC compared with paired normal tissues (Fig. 1A) . Subsequent validation was conducted by analyzing sequencing results from a published database-the Cancer Genome Atlas (TCGA). As expected, COL23A1 expression was significantly increased in 72 ccRCC tissues than paired ANTs (P < 0.001, Fig. 1B) .
Similar to the profiling data, among 12 pairs of comparative freshly collected tissues, 11 paired specimens indicated elevated protein expression levels of COL23A1 in ccRCC tissues compared with corresponding ANTs (Fig. 1C) . Furthermore, immunohistochemistry (IHC) performed in 151 ccRCC tissue samples revealed that COL23A1 protein was mainly localized in cytoplasm with or without cytomembrane staining ( Fig. 2A-D) , while COL23A1 expression was low in normal kidney tissues (Fig. 2E,F) .
Correlation between COL23A1 expression levels and patient characteristics. For the 151 ccRCC tissues evaluated by IHC, COL23A1 expression levels and clinicopathological parameters are listed in Table 1 . COL23A1 expression status was not associated with age (P = 0.316), sex (P = 0.420), Eastern Cooperative Oncology Group (ECOG) performance (P = 0.286), International Society of Urological Pathology (ISUP) grade (P = 0.877), and necrosis (P = 0.914). There was a significant correlation between high COL23A1 expression and larger tumor size (P = 0.017). For tumor diameter ≤ 4 cm, only 41.7% (43/103) of tumors had high COL23A1 expression; however, this proportion increased to 62.5% (30/48) for tumors larger than 4 cm (P = 0.017). COL23A1 expression was more common in tumors with advanced T stage (70.4%, 19/27) than in T1 stage tumors (43.5%, 54/124; P = 0.011).
Clinical outcome according to COL23A1 expression. Kaplan-Meier survival analysis was applied to compare overall survival (OS) according to COL23A1 expression. Patients with high COL23A1 expression had significantly worse OS (P = 0.002; Fig. 2G ). The prognostic value of each clinicopathological factor, including COL23A1 expression status, was evaluated for OS (Table 2) . Univariate Cox proportion hazard ratio (HR) analysis showed that tumor size (HR: 3.437, P = 0.001), ECOG performance (HR: 6.259, P = 0.000), T stage (HR: 6.449, P = 0.000), ISUP grade (HR: 2.944, P = 0.001), necrosis (HR: 4.628, P = 0.002), and COL23A1 expression status (HR: 3.459, P = 0.004) were associated with OS. Further, ECOG performance (HR: 4.762, P = 0.000), T stage (HR: 2.724, P = 0.037), ISUP grade (HR: 2.077, P = 0.024), and COL23A1 expression (HR: 3.024, P = 0.017) were identified as independent prognostic factors of OS by multivariate analysis. (Fig. 3B) . Decreased levels of COL23A1 mRNA (Fig. 4A,B) and protein (Fig. 4C,D) were observed in 786-O and A-498 cell lines after treatment with three siRNA sequences specifically targeting COL23A1 mRNA. As shown in Fig. 4, siRNA#1 and siRNA#2 demonstrated the highest interference efficiency, and were therefore selected for use in further experiments. Fig. 5A ) and of A-498 cells treated with siRNA#1 ( Fig. 5B) showed obvious suppression of proliferation compared with cells treated with siNC. Next, a fluorescence-activated cell sorting assay was employed to investigate whether the inhibition of ccRCC cell proliferation upon knockdown of COL23A1 is associated with cell cycle arrest. Flow cytometry results indicated that COL23A1 knockdown ccRCC cells had a larger G0/G1 population and a decreased S phase population compared with the siNC group for both cell lines (Fig. 5C ), indicating that COL23A1 knockdown blocked cell cycle progression. To examine whether COL23A1 is involved in cell adhesion, we measured ccRCC cells adhesion to fibronectin, one of extracellular matrix components. Knockdown of COL23A1 in 786-O cells resulted in decreasing adhesive ability (Fig. 6A) . Similar results were obtained in A-498 cells (Fig. 6B) . Therefore, western blot analysis was used to examine changes in a series of proteins with known roles in cell adhesion, including E-cadherin, N-cadherin, α-catenin, β-catenin and γ-catenin [20] [21] [22] . Silencing of COL23A1 in 786-O ( Fig. 6C ) and A-498 ( Fig. 6D ) cells led to decreased protein levels of N-cadherin, α-catenin, β-catenin and γ-catenin, while increased protein level of E-cadherin. These results revealed a pivotal role of COL23A1 in cell adhesion in ccRCC. Furthermore, Transwell assays were also performed to measure the migration ability of ccRCC cells. COL23A1 RNA interference of 786-O and A-498 cells remarkably attenuated the migration ability by 50-55% compared with the corresponding control (Fig. 6E) .
Discussion
In the present study we investigated the expression pattern, clinical significance, and biological functions of COL23A1 in ccRCC, including proliferation, cell cycle progression, cell adhesion and migration. COL23A1 expression was elevated in ccRCC tissues compared with ANTs and was associated with poor prognosis of ccRCC patients. Moreover, we demonstrated that knockdown of COL23A1 inhibited ccRCC cell proliferation, which was correlated with inhibition of cell cycle progression, and also attenuated the cell adhesion and migration capability of ccRCC cells. Investigations of COL23A1 in many malignancies have implicated an important role in tumor maintenance [15] [16] [17] [18] . Banyard et al. originally discovered that collagen XXIII is upregulated in the highly metastatic rat prostate carcinoma subline AT6.1 compared with lower metastatic potential sublines 15 , suggesting a close correlation between collagen XXIII expression and prostate cancer metastatic behavior. Furthermore, collagen XXIII was experimentally validated as a reliable biomarker for recurrence and distant metastases in prostate cancer patient samples. Moreover, a reduced level of collagen XXIII in urine of prostate cancer patients was reported after prostatectomy 16 . The same study also reported that COL23A1 was upregulated in prostate cancer tissues, and might be an independent predictor of PSA-defined disease recurrence 16 . Spivey et al. showed that COL23A1 had potential as a tissue and urinary biomarker for non-small cell lung cancer 17 . Several studies have also showed clues about the relationship between COL23A1 expression and ccRCC. One previous research stated that COL23A1 mRNA distribution was restricted and expression was very low in mouse tissues, and signals were very low in human kidney 23 . Another study reported that collagen XXIII protein could be detected in samples of ccRCC patients using immunohistochemical staining 17 . By conducting whole-genome expression profiling on 101 pairs of ccRCC tumors and adjacent non-tumor renal tissues, Wozniak et al. identified 1650 significantly differential expression genes. When matching them with the TCGA RNA-Seq dataset, they found that COL23A1 were overexpressed in both datasets 19 . We observed a higher level of COL23A1 mRNA and protein in clinical ccRCC tissues compared with matched ANTs. The mRNA level of COL23A1 was further validated by TCGA database, which showed significantly increased COL23A1 expression in 72 ccRCC tumor tissues than paired ANTs. In addition to validation Most studies on COL23A1 revealed a close relationship with cell adhesion, invasion, and metastasis. Exogenously expressed recombinant COL23A1 competed with corneal epithelial cell surface COL23A1 for binding to collagen IV and Matrigel 24 , and COL23A1 directly interacted with integrin α2β1 and sufficiently induced integrin α2β1-dependent attachment and spreading of keratinocytes 25 , corroborating the results of Spivey et al., who reported that COL23A1 played a role in cancer cell adhesion, anchorage-independent growth, and metastasis 17 . Our research demonstrated that knockdown of COL23A1 attenuated ccRCC cell adhesion and migration in vitro. Moreover, COL23A1 promoted ccRCC cell proliferation and cell cycle progression. Three days after silencing of COL23A1, the proliferation of 786-O and A-498 cells was significantly inhibited compared with cells in control groups. Furthermore, knockdown of COL23A1 induced cell cycle arrest in G0/G1 phase, which may partially account for the inhibitory effect on the proliferation of ccRCC cells.
To the best of our knowledge, this is the first comprehensive study establishing that COL23A1 plays an oncogenic role in ccRCC tumorigenesis and progression and has the potential to be a novel biomarker for predicting prognosis of ccRCC patients. However, some limitations of our study should be addressed. First, this was a single-center pilot study and the prognostic value of COL23A1 was not validated in another independent cohort. Second, the exact mechanism by which COL23A1 promotes ccRCC progression was not investigated. Thus, large-scale examinations of COL23A1 expression in ccRCC patients and further explorations to elucidate the underlying molecular mechanisms are required.
In conclusion, our results demonstrated that COL23A1 expression is significantly increased in ccRCC tissues. COL23A1 overexpression was correlated with more aggressive tumor behavior. In addition, upregulation of COL23A1 expression was associated with poor prognosis of ccRCC. In vitro experiments showed that COL23A1 knockdown repressed proliferation by blocking cell cycle progression, and also attenuated the cell adhesion and migration capacity. These findings suggest that COL23A1 may be a novel prognostic indicator in ccRCC and might also be a specific and accessible biomarker as well as a potential new target for clinical diagnosis of ccRCC.
Materials and Methods
Patients and tissue samples. Tissue specimens were obtained from patients with ccRCC who underwent partial or radical nephrectomy from January 2005 to December 2008 at Fudan University Shanghai Cancer Center (FUSCC). None of the patients received preoperative or postoperative adjuvant anticancer therapy. A total of 151 patients with localized ccRCC were included in the IHC analysis. All patients had paraffin-embedded tissue blocks available for IHC staining and outcome data. We also included 31 pairs of comparative freshly collected tissues from localized ccRCC, among which 19 were analyzed by mRNA expression profiling and 12 were subjected to protein expression analysis by western blot. Patient medical records were reviewed to collect demographic data, ECOG performance status, pathological findings, clinical outcomes, and follow-up information. Tumor sizes were defined as the largest diameter of the surgically removed tumor mass. Patients received regular follow-up through telephone calls or clinic visits every 3 months until August 2015 or until the date of death. The study was carried out in accordance with the ethical standards of the Declaration of Helsinki II and approved by the Institution Review Board of Fudan University Shanghai Cancer Center. Informed consent was obtained from each patient and the study was approved by our Institutional Ethics Committee. A data set from an independent cohort in the TCGA database was used for the validation of COL23A1 expression. 5′-GGACUAGCGAAGAUCCGGA-3′, #2: 5-CGAGGGUCUAGCUCUACCA-3′, and #3: 5′-GGAAG CUCCAUCCGAAUGU-3′) and mock siRNA negative control (siNC: 5′-UUCUCCGAACGUGUCACGU-3ʹ) were chemically synthesized (Biotend, Shanghai, China). For transfection, ccRCC cells were seeded in six-well plates at 50-70% confluency. COL23A1 siRNAs were transfected with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. At 48 hours after transfection, the cells were used for the following assays.
Cell lines and cell culture.
RNA extraction and quantitative real-time polymerase chain reaction. A total of 19
pairs of ccRCC and ANTs were randomly collected during surgery of ccRCC patients. Total RNA was extracted from the cell lines and patient samples using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. After quantification using NanoDrop-2000 (Thermo Fisher Scientific, Wilmington, DE, USA), total RNA was reverse transcribed to cDNA using PrimeScript RT Master Mix (Takara, Shiga, Japan) and subjected to qRT-PCR using an ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA). β-actin was used as the endogenous control to calculate relative gene expression levels by the comparative cycle threshold (CT) (2 -ΔΔCT ) method. The following primers were used in this study: 5′-AGGTTCTTACAGGGCAGTA-3′ (forward) and 5′-TAACATTCAAGAGTATGCCCACC-3′ (reverse) for COL23A1; 5′-CTACGTCGCCCTGGACTTCGAGC-3′ (forward) and 5′-GATGGAGCCGCCGATCCACACGG-3ʹ (reverse) for β-actin.
Western blot analysis. Standard Immunohistochemistry analysis. Tissue sections were deparaffinized in xylene and rehydrated in graded alcohols. Endogenous peroxidase was blocked by incubation with 3% hydrogen peroxide (Sigma-Aldrich, USA) diluted in methanol for 15 min at 15 °C. Heat-induced antigen retrieval was conducted in 10 mM citrate buffer solution (pH = 6.0). Immunohistochemical staining was performed using an avidin-biotin-peroxidase complex method. Slides were blocked using normal goat serum followed by the avidin/biotin blocking kit and incubated with anti-COL23A1 antibody (1:200, Catalog # MAB4165, R&D Systems, Minneapolis, Minnesota, USA) at 4 °C overnight. Slides were then sequentially incubated with biotinylated goat anti-rabbit IgG for 1 h at 37 °C and with preformed avidin-biotin complex. Specifically bound COL23A1 proteins were visualized by staining with 3,3ʹ-diaminobenzidine tetrahydrochloride. Slides were counterstained with Mayer's hematoxylin, dehydrated, and mounted.
All slides were examined and scored in an open discussion by two experienced pathologists, who were blinded to the outcome and clinical data. The COL23A1 immunostaining was measured based on the intensity of staining (intensity score) and the quantity of immunoreactive cells (quantity score), as previously reported 26 . The intensity of immune staining was scored as 0, negative; 1, weak; 2, moderate; and 3, intense. The quantity of immunoreactive cells was scored as 0%, none; 1, 1%-30%; 2, 31%-60%; 3, >60%
27
. The product of intensity score and quantity score was used as the total score, in which 0-3 indicates low expression and 4-9 indicates high expression 28 . Migration assay. Boyden Transwell chambers (8 μm, 24-well format; Corning Co., New York, NY, USA) containing 8-μm membrane filters were applied to 24-well plates. A total of 2 × 10 4 cells suspended in 200 µL FBS-free medium were placed in the upper well, and culture medium supplemented with 10% FBS was added to the bottom chamber. After incubation for 24 h or 48 h at 37 °C, the cells on the upper surface were wiped off and cells on the lower surface were fixed with 4% paraformaldehyde solution and stained with 0.1% crystal violet. The average number of migrated cells was counted in five randomly selected fields under a microscope. Experiments were independently repeated in triplicate.
Statistical analysis. The significance of between-group differences was estimated using Student's t-test, chi-square test, or Wilcoxon test, as appropriate. Univariate and multivariate Cox regression models were performed to evaluate the prognostic value of all parameters. OS for patient groups classified according to tumor COL23A1 expression level was calculated by the Kaplan-Meier method and compared using the log-rank test. All statistical tests were performed using SPSS version 20 (SPSS Inc., Chicago, IL, USA). Two-tailed P values < 0.05 were considered statistically significant. Significance was indicated as *P < 0.05, **P < 0.01, and ***P < 0.001. 
